Regulus Inks miRNA Drug R&D Deal with Sanofi-Aventis Worth up to $750M

The deal gives Sanofi worldwide, exclusive rights to use Regulus' technology and know-how to discover, develop, and sell four miRNA drugs.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.